Metagenomi Therapeutics, Inc. Common Stock (MGX) — Analysis Summary
Metagenomi Therapeutics, Inc. Common Stock (MGX) has a market cap of $49.69M with year-over-year revenue growth of -51.8%. Net margin stands at -348.5%. The stock trades at a P/E ratio of -0.6.
Key Takeaways
- Revenue changed -51.8% year-over-year
- Net margin of -348.5%
- P/E ratio of -0.6
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, MGX posted revenue growth of -51.8% and trades at a P/E of -0.6.
Metagenomi Therapeutics, Inc. Common Stock (MGX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -415.5% — severe operating losses
Net margin at -384.6% — losses exceed revenue (possible one-time charges)
Revenue declined 11.4% vs the prior period.
The latest filing shows negative free cash flow.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
118
Headquarters
EMERYVILLE, CA
Exchange
XNAS
At least 3 years of annual financial data required to assess competitive moat.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.